To tackle aging as a major risk factor for chronic disease, we need to develop a more aggressive public-private investment strategy in prevention and health promotion.
On the private side, as the Medicines in Development for Older Americans report shows, biopharmaceutical research companies are developing over 400 medications for the top chronic diseases to allow these older adults to live a better and in some cases longer life.
Patient Reported Outcomes as a Means to Reaching Effective Quality Measurement
06.17.14 | By
A recent Roundtable in Washington D.C. underscored why, with the growing focus on value-based payment in health care, it’s more important than ever to focus on the patient. We can’t advance patient-centered care if we aren’t measuring and incentivizing what matters to patients. We have begun to see this shift in the premarket arena via patient-focused drug development and in comparative effectiveness research at the Patient-Centered Outcomes Research Institute.
Like both sides of a coin, there are two sides in the battle against cancer. We are making huge strides in preventing, slowing and in some cases beating many forms of cancer, but there are still considerable roadblocks to reaching our ultimate goal of a world free from cancer.
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine. Due to increased costs, patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition. The Affordable Care Act and Health Insurance Exchanges were intended to address the need for affordable care. The new Avelere study supports the patient stories we often hear.
As reported in the June 11, 2014 Avalere study examining cost sharing in silver exchange plans, many drugs for patients with chronic conditions enrolled in silver exchange plans are priced as to be unaffordable, creating access barriers for many patients for whom the landmark Affordable Care Act was particularly designed. This study exposes a genuine flaw in a key part of the Act which especially impacts the 25 percent of enrollees in exchanges who are between the ages of 55 and 64. People as they age find their prescription drug costs rise, in part due to increases in chronic conditions.